CRISPR therapy for sickle cell anemia and beta thalassemia has helped children under 12.
Researchers from seven countries presented preliminary results from a Phase 3 ex vivo clinical trial of CRISPR therapy for severe forms of sickle cell anemia and beta thalassemia in children under 12 years of age. The drug's efficacy in the first few…